Creatine monohydrate doesn’t appear to slow the progression of Parkinson’s disease, according to research published in the February 10 issue of the Journal of the American Medical Association (JAMA).
The new study included 1,741 people in the United States and Canada who had been diagnosed with Parkinson’s disease within the previous five years. All were receiving treatment for Parkinson’s disease. As part of the study, they were randomly assigned to take creatine monohydrate or a placebo in addition to their usual treatment.
The patients were enrolled from March 2007 to May 2010 and followed up until September 2013. The study was halted early because those taking creatine showed no differences in disease progression compared to those taking the placebo.
“These findings do not support the use of creatine monohydrate in patients with Parkinson’s disease,” study author Karl Kieburtz, MD, MPH, of the University of Rochester in New York, and colleagues write.